基于血液的肥胖生物标志物及其与疾病风险相关性的研究
Tobias Pischon1,2,3, Katharina Nimptsch4
1Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany. tobias.pischon@mdc-berlin.de.
Nature reviews. Endocrinology
|January 15, 2026
概括
肥胖会增加慢性疾病的风险,但机制尚不清楚. 血液中的脂肪组织生物标志物,通过omics和传统方法确定,可能会调解这些风险,需要进一步研究.
科学领域:
- 生物医学科学 生物医学科学
- 代谢性疾病研究研究
- 肥胖医学 肥胖医学
背景情况:
- 肥胖是慢性疾病和过早死亡的重要危险因素.
- 将体脂肪组织增加与胰岛素抵抗和炎症等疾病途径联系在一起的确切机制仍然不完全理解.
- 脂肪组织衍生的血液生物标志物,包括adipokines,炎症性细胞因子和性类固醇激素,被认为是潜在的调解者.
研究的目的:
- 审查脂肪组织衍生的基于血液的肥胖生物标志物.
- 讨论它们与慢性疾病风险的相关性以及它们作为调解者的潜在作用.
- 突出生物标志物发现的演变,从传统方法到现代的奥米克方法.
主要方法:
- 审查关于肥胖生物标志物的现有文献.
- 讨论人类生物标志物相关性的传统流行病学方法.
- 将蛋白质组学和代谢组学研究的见解融入人类观测研究中.
- 考虑因果推理的门德尔随机化研究.
主要成果:
- 蛋白质学和代谢学已经部分证实了传统的肥胖生物标志物.
- 几种脂肪组织衍生生物标志物被提议作为将肥胖与疾病联系起来的媒介.
- 目前基于omics和传统的生物标志物需要通过大规模的前性研究进一步验证.
结论:
- 脂肪组织生物标志物在了解与肥胖相关的疾病机制方面发挥着至关重要的作用.
- 生物标志物发现已经与奥米克技术取得了进展,补充了传统方法.
- 大规模的前性研究对于确定肥胖生物标志物的临床相关性至关重要.
相关概念视频
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
01:21Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
540
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
540
01:24Overview of Lipid Metabolism
4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169